76% of healthcare organizations have more AI pilot programs than they can scale. Kyndryl’s Healthcare Readiness Report, released March 5, 2026, found that number after surveying health IT leaders nationwide. Three weeks later, at HIMSS 2026 in Las Vegas, that statistic didn’t land as a warning. It landed as a confession.
Health systems aren’t failing at AI because the technology is broken. They’re failing because the adoption model they inherited from traditional software procurement doesn’t apply to clinical AI. And most organizations haven’t yet confronted that mismatch in any meaningful way.
The Problem: Pilot Purgatory
The standard playbook goes like this: a vendor runs a demo, clinical leadership gets excited, procurement signs a contract, IT deploys the tool, and a 90-day pilot launches with a hand-selected cohort of enthusiastic early adopters. The pilot succeeds. Results get reported upward. A slide deck is built for the board meeting. And then nothing. The tool never reaches the next unit, the next facility, or the adjacent workflow. It lives in permanent pilot status, funded just enough to survive but never enough to scale.
This is pilot purgatory. 80% of healthcare AI projects never escape it. A separate MIT analysis found that enterprises globally are investing $30 to $40 billion in generative AI, and more than 95% are seeing no measurable ROI. Healthcare is not outperforming that benchmark.
Providence Health System’s Chief Information and Digital Officer, Cherodeep Goswami, said it directly at HIMSS 2026: the real challenge isn’t deploying a tool. It’s driving adoption past 60% and proving ROI through unglamorous work that follows go-live. His organization is among the most sophisticated AI adopters in the country. They’re still fighting for that number.
Three structural failures kill the scale-up. None of them are technical.
1. No One Owns the Workflow
The vendor owns the platform. The CMO owns the strategy. IT owns the infrastructure. Nobody owns the day-to-day process changes required to make the tool work for a clinician in front of a patient. When the vendor’s implementation lead rolls off after 90 days, the tool starts degrading. By month six, workarounds emerge. By month twelve, adoption sits at 22% and nobody can articulate why.
2. ROI Is Measured Like Capital Equipment
Upfront cost versus projected savings is a framework built for infusion pumps and MRI machines. It doesn’t work for AI. A clinical AI tool doesn’t produce savings on day one. It produces leading indicators: clinician time recaptured, decision latency reduced, near-miss events avoided. If your finance team is evaluating AI ROI the same way they evaluate a capital lease, they’ll cut a tool that’s working because the value isn’t visible in the standard report.
3. Pilots Run in the Wrong Conditions
Your pilot cohort is almost always your most enthusiastic early adopters. They succeed. Leadership celebrates. The rollout expands, makes contact with a resistant unit, and collapses. The clinical AI tool that survives at enterprise scale isn’t the one that performed best in a controlled pilot. It’s the one designed to function in hostile workflow environments from the beginning.
“80% of healthcare AI projects never scale. The problem isn’t the algorithm. It’s that no one in the organization owns the workflow the algorithm is supposed to run in.”
The Insight: What Actually Scales
One data point explains why ambient documentation AI is the only use case where 100% of surveyed health systems have initiated adoption and 53% report a high degree of success: it maps directly to an existing, painful workflow problem. Clinicians just talk. ROI shows up in minutes-per-encounter within the first week. No behavior change required. No custom dashboard needed to see the impact.
Every AI deployment that scales at enterprise level shares those three characteristics. It targets a specific, documented pain point. It minimizes the behavior change required to generate value on day one. And it produces ROI that’s observable using data the organization already has, within 30 to 60 days.
The inverse is equally reliable. AI tools that fail at scale try to do too much, require clinicians to adapt their workflow to the tool’s logic rather than the reverse, and deliver ROI that takes six months of analysis to surface. That’s not a value problem. That’s a design and deployment problem.
In pharmacy operations specifically, this pattern repeats with near-perfect consistency. Prior authorization AI promises a 40% reduction in intake time. It delivers that, for 60 to 90 days, while the vendor’s implementation team is still embedded. Then the team rolls off. A workflow edge case breaks the integration. Nobody internally knows who owns the fix. Pharmacists route around the tool by reverting to manual intake. Within six months, adoption is at 20%. The vendor relationship becomes adversarial. The contract gets cancelled. The AI strategy “failed.”
The tool didn’t fail. The ownership model failed.
This matters because the opportunity in pharmacy is real and measurable. Pharmacists currently spend up to 90% of their time on administrative tasks rather than direct patient care. Pharmacy automation ROI is documented: pharmacist productivity improvements of up to 33% and error rate reductions approaching zero in optimized central fill models. That value exists. It’s not being captured because the deployment model treats workflow redesign as a post-launch afterthought rather than a core deliverable.
Real-World Application: The 3-Gate Scale Framework
Before any healthcare AI tool is cleared for enterprise deployment, it should pass three gates — not as a compliance checklist, but as a forcing function that surfaces structural gaps before they become expensive in production.
Gate 1: Named Workflow Owner. If you cannot name a specific individual in your organization who owns the clinical workflow this tool operates in, you are not ready to scale. Not the vendor relationship. Not the IT configuration. The actual clinical work, on the floor, every shift.
Gate 2: 30-Day Leading Indicators. Require the vendor to specify three metrics their tool moves within 30 days, using data your organization already collects. If they need to build a custom dashboard to demonstrate ROI, that is a red flag — not a technical gap. It means the tool was not designed with your operational context in mind.
Gate 3: Resistant Unit Validation. Run the pilot in your most skeptical clinical unit, not your most enthusiastic one. If adoption doesn’t reach 60% among resistant users, it won’t survive enterprise scale. A successful pilot in your early-adopter unit is a favorable lab result, not a deployment signal.
For telepharmacy and ambulatory pharmacy operations, three workflow areas are best positioned to clear all three gates in 2026: prior authorization intake, discharge medication reconciliation, and formulary exception routing. These processes are already painful, already instrumented with data, and already producing measurable delay at every handoff point. They don’t make for impressive conference presentations. They are exactly where the operational ROI is concentrated.
Only 12.5% of health system leaders report that autonomous AI has delivered meaningful clinical value to date. The organizations gaining ground aren’t deploying more AI. They’re deploying less AI into better-designed ownership structures.
Executive Takeaway: Three Actions This Quarter
Audit your current AI portfolio for Gate 1 failures. List every AI tool in active deployment. For each one, write the name of the person who owns the clinical workflow — not the vendor relationship, not the IT ticket queue, not “the AI governance committee.” One name. If you can’t fill that field, you’ve located your scaling problem. Fix the ownership model before you expand the license.
Redefine ROI requirements before signing your next contract. Require any new AI vendor to specify three leading indicators their tool moves within 30 days, observable using data you already collect. If they need to build a custom dashboard to show you ROI, that is a red flag, not a technical gap. It means the tool was not designed with your operational context in mind.
Run your next pilot in your most resistant clinical unit. If a clinical AI tool can’t reach 60% adoption among skeptical users, it won’t survive enterprise scale. That is the only pilot condition that predicts production performance. A successful pilot in your early-adopter unit is a favorable lab result, not a deployment signal.
“If you don’t have a named owner for every AI-enabled workflow by end of 2026, you’re not behind on AI adoption. You’re behind on operational governance.”